Date: 2016-04-25
Type of information: Collaboration agreement
Compound: pharmacogenetics tests (5-FUODPM Tox ™, 5-FUODPM Protocol ™)
Company: Biomnis (France) Onco Drug Personalized Medicine (France)
Therapeutic area: Cancer - Oncology - Diagnostic
Type agreement: collaboration
Action mechanism: pharmacogenetics test. 5-Fluorouracil (5-FU), from the Fluoropyrimidine family, is one of the main cancer treatments used in over 60% of cancers. However, using these molecules can cause many, occasionally severe, toxic effects. These toxic effects are due to overexposure to the drug linked to inter-individual variations in metabolic rates. The protocol is based on two complementary approaches to avoiding the severe toxic effects that can be caused by treatments with 5-FU during chemotherapy:
- 5-FUODPM Tox ™ - a test to detect patients with a high toxicity risk.
- 5-FUODPM Protocol ™ - a test that can be performed throughout treatment, using a simple blood test, to ensure that the circulating quantity of 5-FU is appropriate for the patient, and enables dose adjustment as required.
Disease:
Details: * On January 22, 2016, Biomnis, a specialty clinical diagnostics laboratory group in Europe, and a subsidiary of
Eurofins Scientific, announced the launch of a protocol for pharmacogenetics tests following the creation of a cancer treatment partnership with Onco Drug Personalized Medicine (ODPM). ODPM has developed a protocol that can help patients avoid certain severe toxic effects that can be caused by chemotherapy treatments. These pharmacogenetic tests are exclusively performed by Biomnis laboratories in France.
Biomnis and ODPM have created the partnership as part of a common desire to develop personalised treatment in order to provide reliable and innovative tests and improve therapeutic care for patients. Individual patients react differently to treatment depending on their sex, age, genetic disposition or lifestyles. If the drug dosage is too low for a patient, their treatment will be ineffective; if it is too high, the toxic effects can be severe and detrimental to the effectiveness of the treatment. The aim of personalised treatment is to achieve optimum efficiency while eliminating severe side effects.
Financial terms:
Latest news:
